Debanjan Ray, Chief Financial Officer at CytomX Therapeutics, Inc. (CTMX), sold 2,500 shares at $15.47 ($39K) on 2017-07-03, disclosed to the SEC on 2017-07-06.
Scheduled sale ($39k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CTMX | SELL | 2018-10-02 | $55K | — | Filing → |
| CTMX | SELL | 2018-09-06 | $67K | — | Filing → |
| CTMX | SELL | 2018-08-02 | $78K | — | Filing → |